<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>16 Head and neck cancers</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/></head><body><p class="top_nav"><a href="part21.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part23.htm">Далее &gt;</a></p><p style="padding-top: 3pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><a href="part5.htm#bookmark21" class="s95" name="bookmark63">Chapter 16</a><a name="bookmark64">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 55pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="374" height="1" alt="image" src="Image_232.png"/></span></p><p style="padding-top: 4pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><a href="part5.htm#bookmark21" class="h2">Head and neck </a><h2 href="#bookmark21">cancers</h2></p><p class="s5" style="padding-top: 10pt;padding-left: 53pt;text-indent: 0pt;text-align: left;">Gill Barnett and tilak Das</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-top: 13pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">16.1 <span class="h4">Clinical background</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Head and neck cancers are the sixth most common cancer worldwide, with an in- cidence of more than 650,000 cases per year (11,900 in the UK) and a mortality of 330,000 cases per year (4000 in the UK).<span class="s22">1</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">16.2 <span class="h4">Head and neck squamous cell carcinoma</span></p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">16.2.1 <span class="s29">Diagnosis</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">A full clinical assessment which includes flexible fibre-optic naso-endoscopy will reveal the primary site in the majority of head and neck squamous cell carcinoma (HNSCC) patients. In some patients, the primary site will be only apparent on computed tom- ography (CT) or magnetic resonance imaging (MRI). <span class="s22">18</span>F-fluorodeoxyglucose (FDG) positron emission tomography (PET/CT) is performed if the primary tumour is not present on clinical examination and may guide biopsies at examination under anaes- thesia (EUA). PET-CT has a higher detection rate than a combination of contrast- enhanced CT and MRI.<span class="s22">2 </span>In a small number of patient with no obvious primary tumour on PET/CT, EUA will identify suspicious areas, and biopsy will diagnose the primary site in 16–26% of cases; tonsillectomy on the same side as the nodal disease will establish the primary site in a further percentage. Blind biopsies from the naso- pharynx, palatine tonsil, tongue base, and pyriform sinus were commonly performed in the past, but this is not currently standard practice in patients with radiologically and clinically normal findings.<span class="s22">2</span></p><p style="padding-left: 19pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">Recent studies of inclusion of PET/CT in the work-up of patients with an unknown</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">primary show that a primary site is detected in up to 87% (Figure 16.1).<span class="s22">3 </span>The effect- iveness of FDG PET/CT depends to some extent on the investigations prior to FDG PET/CT. The ultimate role of FDG PET/CT is to reduce the number of patients where a primary site cannot be identified.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Locating the primary site in HNSCC can markedly alter the treatment plan to direct treatment with a high dose to the primary cancer and a lower dose to surrounding normal tissue, so reducing morbidity. The human papillomavirus (HPV) status of the tumour is also important as an HPV positive tumour is most likely to have originated from the oropharynx.<span class="s22">4 </span>Irradiation of the oropharynx may be considered in patients with HPV positive disease who present as a carcinoma of unknown primary.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="394" height="178" alt="image" src="Image_233.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 16.1 <span class="s52">patient who presented with squamous cell carcinoma in left neck nodes. Full clinical assessment including flexible fibre-optic nasoendoscopy, showed no primary site. FDG pet/Ct demonstrated intense uptake in the left oropharynx and neck. the</span></p><p class="s52" style="padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">patient underwent eua, bilateral tonsillectomies and directed biopsies and squamous cell carcinoma was found in the left tonsil.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">PET/CT is best performed before EUA to minimize false positive results. In addition to identifying the primary site, FDG PET/CT may detect unexpected nodal disease in the contralateral neck, undiagnosed nodal disease within the mediastinum, metastatic disease, and synchronous second cancers, including cancers linked by a common aeti- ology such as head and neck, oesophageal and lung cancer, and also other common cancers such as colorectal cancer.<span class="s22">4 </span>PET/CT is therefore recommended in patients with more advanced stage head and neck cancer.<span class="s22">5</span></p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">16.2.2 <span class="s29">Staging</span></p><p class="s97" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">16.2.2.1 <span class="s98">Primary site</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">In patients with the established diagnosis of HNSCC the main purpose of imaging is to determine the deep extent of local tumour involvement and the presence of nodal disease. Only very occasionally does imaging suggest an alternative or unexpected diagnosis.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Initial choice between CT and MRI as the main imaging tools will depend on a number of factors, including availability and team preference. In many centres, MR is the preferred modality for imaging oral cavity, nasopharyngeal, and oropharyngeal tumours. High-resolution CT with intravenous contrast may be preferred for patients with primary hypopharyngeal, and laryngeal cancer. CT scanning is very helpful for patients who are unable to tolerate MRI.<span class="s22">6</span></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The MRI protocol used will vary considerably, partly related to: (1) time available on the scanner; (2) the preferences of the head and neck team; and (3) the make of the MRI scanner. In general, high-quality multi-planar data of the primary site, po- tential sites of direct invasion, and areas of predicted nodal drainage are included.<span class="s22">6 </span>MR sequences typically performed include a coronal short tau inversion recovery (STIR) or fat-saturated T2-weighted (T2W) sequence which encompasses the primary</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">tumour and neck, and coronal and/or axial T1-weighted (T1W) images specifically for primary tumour evaluation. Additional information is gained by using intravenous gadolinium, scanning in other planes, and additional sequences. Many centres include one or more of the following: post-gadolinium fat-saturated T1W sequence in the cor- onal and axial planes ± sagittal plane, fat-saturated T2W sequence in the sagittal ± axial ± coronal planes.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Initial assessment of laryngeal cartilage invasion, as with cortical bone and marrow involvement, will be made on the initial staging examination. Imaging may show clearly either no tumour involvement or alternatively definite invasion of tumour through laryngeal cartilage. Laryngeal cartilage calcifies in an irregular manner and it can be particularly challenging to distinguish uncalcified cartilage from early cartilage destruction. The literature suggests that MRI is more sensitive but less specific, that is, occurrence of false negatives is less with MRI compared with CT, but false positives are higher with MRI compared with CT. CT and MRI complement each other; if one is equivocal then the other can be performed.</p><p class="s97" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">16.2.2.2 <span class="s98">Neck</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The presence of metastatic tumour within cervical nodes has a major influence on the treatment plan and determines the likely prognosis in patients with HNSCC. The neck is assessed routinely with the primary site on CT or MRI and imaging will diagnose neck disease in 20% of patients who are thought to have no disease on clinical assessment.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Ultrasound (US) with fine needle aspiration cytology (FNAC) is a useful adjunct to CT and MRI for detection of nodal disease. In expert hands, an accuracy in excess of 90% can be achieved. When compared with diagnostic imaging, FDG PET/CT is similar or slightly superior for detecting abnormal cervical lymph nodes, but is gener- ally reserved for patients with nodes not accessible to US, for example mediastinal and retropharyngeal nodes, and in cases where US does not provide the diagnosis.<span class="s22">6</span></p><p class="s97" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">16.2.2.3 <span class="s98">Distant metastases</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">CT scan of the thorax is usually performed to look for evidence of metastatic disease. In patients with a high risk of distant metastases, such as locally advanced disease (T3/4, N2/3) and tumours arising from subsites that have a particular predilection to metastasize, for example nasopharyngeal cancer, FDG PET/CT is recommended (Figure 16.2).<span class="s22">6 </span>PET/CT should be included in the routine diagnosis of patients with stages II–IV HNSCC, as it significantly improves staging accuracy and also has a marked impact on management plans. In addition, PET/CT is an accurate method of detecting second primaries with a high negative predictive value. However, add- itional diagnostic methods are necessary to exclude false-positive results.<span class="s22">6</span></p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">16.2.3 <span class="s29">Radiotherapy planning</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Localization of tumour volume and delineation of normal structures is based on CT complemented by MRI. The inclusion of FDG PET/CT may result in substantial change in CTV definition compared to conventional CT alone, leading to more accur- ately targeted radiotherapy fields. There is also evidence that FDG PET/CT improves consistency in volume definition between different operators. There is, however, at</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="303" alt="image" src="Image_234.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 16.2 <span class="s52">patient with a poorly differentiated nasopharynx carcinoma and bilateral neck nodes. MRi showed a right nasopharyngeal mass that extends superiorly into the right head of the clivus and right cavernous sinus, surrounding the inferior carotid siphon and anterior petrous carotid canal, extending into the right sphenoid sinus (a–b). FDG pet/ Ct showed uptake at the primary site and in the neck on both sides (c–d). it also showed unexpected focal uptake in the sacrum (e). MRi pelvis confirmed a lesion in s3. the Rt treatment plan was modified as a result of the FDG pet/Ct.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">present a paucity of evidence to show that this translates into improvements in local control or toxicity.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Tumour edge definition using FDG PET/CT has not yet been standardized.<span class="s22">6 </span>The main limitation is that it is a highly operator-dependent process, and it is influenced by window-level settings. Isocontouring based on a fixed standardized uptake value (SUV), such as 2.5 -3 gl<span class="s22">-1 </span>or relative thresholds such as percentage of the maximum tumour intensity (e.g. 40% SUVmax) may be used. More elaborate methods are being developed such as those based on signal-to-noise ratios, tumour dimension and grade, and gradient-based detections to refine delineation of tumour margins.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Recent studies have shown that functional imaging with MR and PET/CT may be used to provide information on the biological status of regions within HNSCC and to identify radio-resistant subregions that could be targeted for higher doses of radiation using intensity modulated radiotherapy (IMRT).<span class="s22">7</span></p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">16.2.4 <span class="s29">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">On CT and MRI the features which suggest residual tumour or recurrence include the presence of one or more soft tissue masses enlarging on sequential scans, especially if</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: right;">associated with bone or cartilage destruction. Other features, although less specific, that raise the suspicion of recurrence include focal soft tissue swelling &gt;1 cm, that cannot be readily explained by post-surgical appearances, such as those due to a re- construction flap and any abnormal soft tissue which shows enhancement with intra- venous contrast 6 weeks or more after surgery and 12 weeks or more after radiotherapy. Because many changes that follow intervention may be confused with or mask tu- mour recurrence, many experts consider a baseline CT or MRI during the interval when most alterations due to treatment have resolved and there is only little chance of tumour recurrence. Four to eight weeks post-treatment seems to be the best com- promise, but there is a lack of published guidelines. Even with a baseline scan in many patients the early diagnosis of recurrent disease while it is still amenable to treatment</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">remains a challenge.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">PET/CT is very useful in assessing response to treatment. The negative predictive value (NPV) is very high, so a negative study is very suggestive of absence of residual disease. PET/CT should ideally be performed 12 weeks after treatment is complete. The PET-NECK study showed that PET-CT-guided surveillance resulted in fewer neck dissections, similar survival outcomes, and improved cost effectiveness compared with planned neck dissections.<span class="s22">8,9 </span>In addition to more accurate assessment of the post- treatment head and neck, FDG PET/CT detects unexpected distant metastases and will from time to time diagnose synchronous cancers.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">16.2.5 <span class="s29">Surveillance</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Preliminary studies show FDG PET/CT can detect subclinical recurrent disease. One of the largest studies included 388 patients who had undergone radical chemoradiotherapy. In this study 95% of asymptomatic recurrences occurred within two years of follow- up.<span class="s22">10 </span>Further work needs to be done to clarify the role of FDG PET/CT in the sur- veillance of HNSCC patients, including the optimal time points when FDG PET/CT should be considered and especially in those with a high risk of relapse.<span class="s22">6</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">16.3 <span class="h4">Salivary gland tumours</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">US is the usual initial investigation for patients with suspected tumours of the sal- ivary glands; it is quick, cheap, and often no further imaging will be required. This is especially the case when the mass is small, clinically benign, easily localized, and delineated, as with the classic and common pleomorphic adenoma lying superficially in the parotid gland. US will determine the location of the lesion, particularly whether or not it lies within a major salivary gland or outside it (e.g. a lymph node or asym- metric masseteric muscle hypertrophy). It will also often provide a confident diag- nosis of the nature of the lesion, based on its US anatomy, echogenicity, and marginal definition. US-guided biopsy can be performed. The main limitation of US is its in- ability to accurately assess the extent of disease deep to the parotid gland, beyond the stylomandibular canal. CT and MRI are useful in this situation and MRI has the add- itional benefit of more accurate assessment of skull base invasion.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">As a general rule, the vast majority of benign tumours are well-defined on all mo- dalities. Salivary gland malignancies show a broad spectrum of appearances from</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">relatively well-defined benign appearing masses to ill-defined clearly invasive lesions. The commonest salivary gland malignancy encountered is the mucoepidermoid car- cinoma. These lesions show a variable degree of malignancy. Low-grade tumours ap- pear similar to benign lesions, showing well-defined margins and a signal intensity on MRI similar to pleomorphic adenomas. They may be associated with cystic areas which may be complicated by rupture and inflammation, necrosis, and haemorrhage. In keeping with cystic lesions anywhere in the body these processes can alter the ap- pearances on MRI. Generally, the presence of blood or a significant amount of pro- tein or mucin will produce high signal on both T1W and T2W sequences. There may be a layering effect with blood products and debris settling posteriorly. High-grade carcinomas are ill-defined and more cellular, appearing more homogeneous and with a lower signal intensity on the T2W sequence. FDG PET/CT is of limited value for distinguishing between benign and malignant salivary gland tumours as both can be intensely avid for FDG.</p><p style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">Adenoid cystic carcinomas, in common with other malignancies in the head and</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">neck may show some variable reduction in signal on the T2W sequence and there is some evidence that the degree of reduction correlates with increased cellularity and a higher grade of malignancy. Regardless of site of origin (major salivary gland or ectopic salivary gland tissue) adenoid cystic carcinomas show a predilection for perineural invasion and classically extend into skull base foramina and then intra- cranially. Where extension is gross, CT may demonstrate tumour along the cranial nerves and widened foramina. More subtle perineural/neural invasion is better seen with MRI following intravenous gadolinium.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Diagnosis of recurrent adenoid cystic carcinoma can be a challenge on imaging, including FDG PET/CT. In this situation a positive scan is useful but a negative scan cannot exclude recurrent disease. Perineural invasion cannot be reliably diagnosed on FDG PET/CT, and MRI with gadolinium is usually superior.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Adenocarcinoma within the parotid typically has ill-defined margins and is locally invasive. It can be a primary tumour of the gland or a metastatic deposit within lymph nodes in the salivary gland. Consequently, imaging should be extended to search for possible primary sites with CT chest (for carcinoma of the bronchus), abdomen, and pelvis (for gastrointestinal, pancreatic, and renal carcinomas), and, where appropriate, clinical or mammographic assessment of the breasts.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Squamous cell carcinoma within the parotid, with its typically similar imaging ap- pearance to adenocarcinoma, is more likely to be metastatic. It is most often due to spread from a local primary site such as the scalp and external auditory canal. However, if the primary site is not obvious clinically, CT of the chest should be considered, as likely primary sites include the bronchus and thoracic oesophagus.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">16.4 <span class="h4">Thyroid cancer</span></p><p class="s97" style="padding-top: 9pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">16.4.1 <span class="s29">Background</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Thyroid cancer is a relatively uncommon condition but most countries have shown a significant increase in thyroid cancer over the last 30 years. Thyroid cancer is</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">responsible for 567,000 cases worldwide, ranking in ninth place for incidence. The global incidence rate in women of 10.2 per 100,000 is three times higher than in men.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">16.4.2 <span class="s29">Diagnosis</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The vast majority of thyroid cancer is differentiated and will present with a mass or swelling in the neck. US is the key imaging modality for diagnosis, usually com- bined with fine needle aspiration or core biopsy. Features suggestive of papillary car- cinoma, the commonest cancer, include ill-defined margins, reduced echogenicity, microcalcification (25–40%) (Figure 16.3), and, in up to 30% of cases, cystic areas, irregular margin, and ‘taller than wide’ shape (anterior/posterior (AP) &gt; transverse (TR) diameter when imaged in the axial plane).<span class="s22">11</span></p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Follicular carcinoma is notoriously non-specific in appearance at US, usually ap- pearing well-defined and similar to a benign adenoma (Figure 16.4). Colour flow Doppler of a thyroid nodule may be of some assistance. Chaotic intranodal vascular flow suggests a malignant lesion, while benign nodules typically have absent or only peripheral flow.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">For more overtly invasive carcinomas of all types (including the rare undifferenti- ated carcinomas) US features are more obviously malignant, with the tumour being ill-defined and invasive both within the thyroid gland and extending into adjacent structures.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">16.4.3 <span class="s29">Staging</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Most patients do not require further preoperative staging investigations. A minority, however, will have clinically (or ultrasonographically) locally advanced tumour at initial presentation. In these circumstances, preoperative staging is indicated, either in those cases for whom thyroidectomy is likely to be unfeasible or inappropriate</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="218" alt="image" src="Image_235.jpg"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 16.3 <span class="s52">longitudinal us image through the left lobe of thyroid shows an ill-defined predominantly hypoechoic mass with areas of punctuate calcification.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="412" height="206" alt="image" src="Image_236.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 16.4 <span class="s52">two patients with follicular carcinoma. (a) transverse us image through the left lobe of thyroid shows an echogenic nodule with well-defined hypoechoic margins and a small cystic focus. (b) transverse us image through the left lobe of thyroid shows a large solid echogenic nodule and lack of cystic change. Both were classified as indeterminate (u3) nodules.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">(advanced undifferentiated carcinoma) or to guide the surgery (Tables 16.1 and 16.2). In these situations imaging is required to describe as accurately as possible the local in- vasion. Tumour may extend into adjacent critical structures (trachea, larynx, pharynx, oesophagus, and the carotid arteries) and inferiorly into the mediastinum.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The recommended pathological staging is by the TNM staging system. There are a number of other postoperative staging systems in use for differentiated thyroid can- cers which are used for assessing prognosis. The TNM and MACIS have been shown to be the best predictors of outcome in validation studies. Recent updates mean that more patients will be classified as lower stage in the eighth edition compared to the seventh edition. This reflects the low risk of death from thyroid cancer for the majority of patients.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Either MRI or CT may be used to assess the neck (Figure 16.5). Protocols are based on the recommendations of the UK Royal College of Radiologists.<span class="s22">13</span></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Intravenous iodine containing contrast media interferes with radioactive iodine up- take by the thyroid for several weeks. It is therefore important to establish with the referring clinician if this is planned before using intravenous contrast.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">MRI and CT have a similar accuracy for predicting local invasion of the oesophagus, trachea, larynx, and recurrent laryngeal nerve (RLN).<span class="s22">14 </span>The main sign of tracheal or oesophageal invasion is a mass contacting 180° or more of the circumference of these organs. Other findings suggesting tracheal invasion are deformity of the lumen, focal mucosal irregularity or thickening, and soft tissue within the trachea. The oesophageal wall is more difficult to evaluate than the trachea because it is not usually distended with air. On MRI, the most suspicious finding for oesophageal invasion is a focal T2 signal in the outer layer of the oesophageal wall. On CT, there may be loss of the normal oesophageal wall and lumen. Invasion of the RLN can be predicted on MRI</p><p class="s24" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Table 16.1 <span class="s52">tnM classification of papillary, follicular, poorly differentiated, hurthle cell and anaplastic thyroid cancer</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:11.3622pt" cellspacing="0"><tr style="height:15pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T primary tumour*</p></td></tr><tr style="height:15pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">tX</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">primary tumour cannot be assessed</p></td></tr><tr style="height:15pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t0</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">no evidence of primary tumour</p></td></tr><tr style="height:15pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t1</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">tumour 2 cm or less in greatest dimension, limited to the thyroid</p></td></tr><tr style="height:15pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t1a</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">tumour 1 cm or less in greatest dimension, limited to the thyroid</p></td></tr><tr style="height:26pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t1b</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 14pt;padding-right: 7pt;text-indent: 0pt;line-height: 111%;text-align: left;">tumour more than 1 cm but not more than 2 cm in greatest dimension, limited to the thyroid</p></td></tr><tr style="height:26pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t2</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 14pt;padding-right: 7pt;text-indent: 0pt;line-height: 111%;text-align: left;">tumour more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid</p></td></tr><tr style="height:36pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t3</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 14pt;padding-right: 7pt;text-indent: 0pt;line-height: 111%;text-align: left;">tumour more than 4 cm in greatest dimension, limited to the thyroid or gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, or omohyoid muscles)</p></td></tr><tr style="height:15pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t3a</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">tumour more than 4 cm in greatest dimension, limited to the thyroid</p></td></tr><tr style="height:26pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t3b</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;line-height: 111%;text-align: left;">tumour of any size with gross extrathyroidal extension invading strap muscles (sternohyoid, sternothyroid, or omohyoid muscles)</p></td></tr><tr style="height:36pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t4a</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 14pt;padding-right: 7pt;text-indent: 0pt;line-height: 111%;text-align: left;">tumour extends beyond the thyroid capsule and invades any of the following: subcutaneous soft tissues, larynx, trachea, oesophagus, recurrent laryngeal nerve</p></td></tr><tr style="height:26pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t4b</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 14pt;padding-right: 13pt;text-indent: 0pt;line-height: 111%;text-align: left;">tumour invades prevertebral fascia, mediastinal vessels, or encases carotid artery</p></td></tr><tr style="height:26pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s106" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">note</p><p class="s106" style="padding-top: 3pt;text-indent: 0pt;text-align: left;">*including papillary, follicular, poorly differentiated, hurthle cell and anaplastic carcinomas</p></td></tr><tr style="height:15pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">N regional lymph nodes cervical and upper mediastinal</p></td></tr><tr style="height:15pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">nX</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">Regional lymph nodes cannot be assessed</p></td></tr><tr style="height:15pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n0</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">no regional lymph node metastasis</p></td></tr><tr style="height:15pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n1</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">Regional lymph node metastasis</p></td></tr><tr style="height:26pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n1a</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 14pt;padding-right: 13pt;text-indent: 0pt;line-height: 111%;text-align: left;">Metastasis in level Vi (pretracheal, paratracheal, and prelaryngeal/Delphian lymph nodes) or upper/superior mediastinum</p></td></tr><tr style="height:26pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n1b</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 14pt;padding-right: 7pt;text-indent: 0pt;line-height: 111%;text-align: left;">Metastasis in other unilateral, bilateral, or contralateral cervical (levels i, ii, iii, iV, or V) or retropharyngeal</p></td></tr><tr style="height:15pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M distant metastases</p></td></tr><tr style="height:15pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M0</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">no distant metastasis</p></td></tr><tr style="height:15pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M1</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">Distant metastasis</p></td></tr></table><p class="s14" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;line-height: 107%;text-align: left;">Reproduced with permission from sobin lh, Gospodarowicz MK, Wittekind Ch. <span class="s83">UICC TNM Classification of Malignant Tumours</span>. 8th ed. © 2017 Wiley Blackwell.</p><p class="s24" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 16.2 <span class="s52">staging of differentiated and anaplastic thyroid cancer</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.6694pt" cellspacing="0"><tr style="height:24pt"><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;line-height: 112%;text-align: left;">Papillary or follicular carcinoma</p></td><td style="width:76pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">Under 55 years</p></td><td style="width:98pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s26" style="padding-top: 1pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">55 years and older</p></td><td style="width:67pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:26pt"><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage i</p></td><td style="width:76pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">any t, any n, M0</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;padding-right: 27pt;text-indent: 0pt;line-height: 111%;text-align: left;">t1 t2</p></td><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 13pt;padding-right: 22pt;text-indent: 0pt;line-height: 111%;text-align: left;">n0 n0</p></td><td style="width:67pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 19pt;padding-right: 34pt;text-indent: 0pt;line-height: 111%;text-align: left;">M0 M0</p></td></tr><tr style="height:15pt"><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage ii</p></td><td style="width:76pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">any t, any n, M1</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">t1</p></td><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">n1</p></td><td style="width:67pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 19pt;text-indent: 0pt;text-align: left;">M0</p></td></tr><tr style="height:15pt"><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:76pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">t2</p></td><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">n1</p></td><td style="width:67pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 19pt;text-indent: 0pt;text-align: left;">M0</p></td></tr><tr style="height:15pt"><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:76pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">t3a/t3b</p></td><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">any n</p></td><td style="width:67pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 19pt;text-indent: 0pt;text-align: left;">M0</p></td></tr><tr style="height:15pt"><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage iii</p></td><td style="width:76pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">t4a</p></td><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">any n</p></td><td style="width:67pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 19pt;text-indent: 0pt;text-align: left;">M0</p></td></tr><tr style="height:15pt"><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage iVa</p></td><td style="width:76pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">t4b</p></td><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">any n</p></td><td style="width:67pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 19pt;text-indent: 0pt;text-align: left;">M0</p></td></tr><tr style="height:15pt"><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage iVB</p></td><td style="width:76pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">any t</p></td><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">any n</p></td><td style="width:67pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 19pt;text-indent: 0pt;text-align: left;">M1</p></td></tr><tr style="height:15pt"><td style="width:158pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Anaplastic or undifferentiated carcinoma</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:67pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:15pt"><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage iVa</p></td><td style="width:76pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">t1–t3a</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">n0/nx</p></td><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">M0</p></td><td style="width:67pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:15pt"><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage iVB</p></td><td style="width:76pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">t1–t3a</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">n1</p></td><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">M0</p></td><td style="width:67pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:15pt"><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:76pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">t3b–t4</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">any n</p></td><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">M0</p></td><td style="width:67pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:15pt"><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage iVC</p></td><td style="width:76pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">any t</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">any n</p></td><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">M1</p></td><td style="width:67pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p class="s14" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 107%;text-align: left;">source: data from sobin lh, Gospodarowicz MK, Wittekind Ch. <span class="s83">UICC TNM Classification of Malignant Tumours. </span>8th ed. © 2017 Wiley Blackwell.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="163" alt="image" src="Image_237.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 16.5 <span class="s52">(a) post-contrast Ct of the neck demonstrates a large right-sided anaplastic thyroid carcinoma (*) involving the right thyroid lamina (arrow) with cartilage destruction and partially encasing the right internal carotid artery (arrowhead). (b) axial fat-suppressed t2-weighted and (c) axial fat-suppressed post-contrast t1-weighted images of the same patient demonstrating the large right-sided thyroid mass involving the right thyroid lamina and extending into the posterior larynx.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 17pt;text-indent: 0pt;text-align: left;"><span><img width="416" height="209" alt="image" src="Image_238.gif"/></span></p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 16.6 <span class="s52">Ct scan demonstrating a large anaplastic carcinoma of the right thyroid lobe containing foci of calcification. there is posterior displacement of the right common carotid artery but no evidence of arterial invasion.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">and CT by effacement of fat in the tracheoesophageal groove where the nerve courses. Other imaging features of RLN invasion are signs of vocal cord dysfunction and 25% or more of the circumference of the primary tumour abutting the capsule at the pos- terior portion of the thyroid (sign of posterior extracapsular invasion). Contact of the thyroid tumour with 270° or more of the circumference of the vessel is a highly specific sign for common carotid artery and internal jugular vein invasion on CT and MRI. Arterial compression or deformation or loss of the fat plane are also radiological signs of vessel involvement.<span class="s22">14</span></p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: right;">CT may produce better quality images than MRI when patients have respiratory dis- tress and have difficulty lying flat due to compromise of the airway by tumour invasion (Figure 16.6). CT is also quicker and superior for the detection of pulmonary metastases. Lymphatic drainage from the thyroid gland is extensive and includes deep and superficial cervical, para- and pretracheal, paraoesophageal, paralaryngeal, supraclavicular, submandibular, and anterior mediastinal lymph nodes. The lymph node groups at highest risk of metastases are the central compartment (level VI, pre- and paratracheal), lower deep cervical (levels III and IV), and the lower half of the posterior triangle (level Vb). Papillary carcinoma has the highest rate of lymph node metastases, in excess of 75% of cases at presentation. The rate of early lymph node spread is also high with both anaplastic and medullary carcinoma, &gt;50%, whereas the</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">rate is low with follicular carcinoma, &lt;20%.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Papillary carcinoma lymph node metastases may show multiple discrete foci of calcifi- cation on CT and areas of reduced (cystic or necrotic change) or increased (intra-nodal haemorrhage or areas of high thyroglobulin concentration) density (Figure 16.7).<span class="s22">14</span></p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">On MR these changes may appear as high signal on the T2W and low, intermediate, or high signal on T1W sequences. Papillary carcinoma may present with abnormal lymph nodes without a primary thyroid lesion demonstrable on imaging.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="178" alt="image" src="Image_239.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 16.7 <span class="s52">Ct scan demonstrating (a) an enlarged right-sided lymph node with cystic change characteristic of papillary carcinoma metastasis. (b) Ct image through the thyroid gland of the same patient demonstrating a region of low density corresponding to the primary tumour.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Lymph node metastases from medullary and anaplastic carcinoma also often show necrotic changes. Consequently MRI and CT are reasonably accurate in the detection of involved lymph nodes both at the time of presentation and in recurrent disease.<span class="s22">14 </span>Accuracy is less for follicular carcinoma, due to the lower incidence of morphological changes in the affected lymph nodes.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">16.4.4 <span class="s29">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Dynamic risk stratification should be performed 6–9 months after radioiodine abla- tion for all patients with R0 disease. This allows potential modification of the post- surgical risk; so, for example, some patients who were deemed high risk after their surgery may be lower risk after a good response to RRA. This facilitates a more per- sonalized approach to treatment, follow-up, and prognosis. Stimulated thyroglobulin is measured and neck ultrasound is performed. Cross-sectional or diagnostic uptake scans may be performed if indicated. The response to initial therapy may thus be div- ided into excellent, indeterminate, or incomplete.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">In patients with an excellent response to treatment, the serum TSH should be sup- pressed to between 0.3 mU/l and 2 mU/l. In patients with an indeterminate response to treatment, the serum TSH should be suppressed to between 0.1 mU/l and 0.5 mU/l for 5–10 years, at which the need for continuing TSH suppression should be re-evaluated. In patients with an incomplete response to treatment, the serum TSH should be suppressed to &lt;0.1 mU/l indefinitely. These high-risk patients need lifelong follow-up, both because of the risk of curable late relapses and to monitor and manage the toxicity of supra-physiological thyroid replacement.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The commonest site of recurrence of thyroid cancer is cervical lymph nodes; recur- rence outside the neck is most often in the chest, usually in the form of pulmonary metastases which are often multiple tiny metastases with a relatively indolent course. The only other common metastases are skeletal.</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Routine follow-up of patients with differentiated thyroid cancer includes examin- ation of the neck or other relevant systems, clinical and biochemical assessment of thyroid status, and serum thyroglobulin measurement (calcitonin levels for medullary thyroid cancer).<span class="s22">12 </span>Abnormal masses in the neck should trigger further investigations, which may include FNA cytology (FNAC). If the thyroglobulin level rises, US of the neck (with biopsy if appropriate) is indicated in the first instance.<span class="s22">12 </span>MRI or CT may then be further used to evaluate positive findings in the neck. CT may also be indi- cated to assess the chest for metastases. FDG-PET/CT is useful in this setting.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">16.5 <span class="h4">Summary</span></p><p class="s23" style="padding-top: 6pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">MRI and CT offer good demonstration of the local extent of head and neck tu- mours; MRI offers better delineation of soft tissue invasion. MRI is the modality of choice for assessing skull base invasion.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">FDG PET/CT may improve detection of occult primary tumours, is a cost-effective single staging investigation in tumours at high risk of metastases, and superior to MRI and CT for detection of recurrent disease.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Superficial salivary tumours and thyroid tumours are best assessed initially with ultrasound.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s73" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">References</p><p class="s74" style="padding-top: 5pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">1. <a href="http://info.cancerresearchuk.org/cancerstats%20and%20Global%20cancer%20statistics%202018" style=" color: #231F20; font-family:&quot;Palatino Linotype&quot;, serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 8.5pt;" target="_blank">CancerStats from Cancer Research UK. Available at: </a><a href="http://info.cancerresearchuk.org/cancerstats%20and%20Global%20cancer%20statistics%202018" class="a" target="_blank">http://info.cancerresearchuk.org/ </a><a href="http://info.cancerresearchuk.org/cancerstats%20and%20Global%20cancer%20statistics%202018" target="_blank">cancerstats and Global cancer statistics 2018</a></p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">2. <b>Rassy E</b>, <b>Nicolai P </b>and <b>Pavlidis N. </b>(2019). Comprehensive management of HPV-related squamous cell carcinoma of the head and neck of unknown primary <i>Head &amp; Neck</i>,</p><p class="s75" style="padding-left: 24pt;text-indent: 0pt;line-height: 11pt;text-align: left;">41<span class="s74">: 3700–3711.</span></p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">3. <b>Albertson M</b>, <b>Chandra S</b>, <b>Sayed Z</b>, <b>Johnson C. </b>(2019). PET-CT evaluation of head and neck cancer of unknown primary. <i>Seminars in Ultrasound, CT, and MRI</i>, <b>40</b>(5): 414–423.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">4. <b>Hohenstein NA</b>, <b>Chan JW</b>, <b>Wu SY, et al. </b>(2020). Diagnosis, staging, radiation treatment response assessment, and outcome prognostication of head and neck cancers using pet imaging: a systematic review. <i>PET Clinic</i>, <b>15</b>: 65–75.</p><p style="padding-top: 1pt;padding-left: 13pt;text-indent: 0pt;text-align: left;"><a href="https://www.nice.org.uk/guidance/qs146/chapter/Quality-statements" class="a" target="_blank">5. </a><a href="https://www.nice.org.uk/guidance/qs146/chapter/Quality-statements" target="_blank">https://www.nice.org.uk/guidance/qs146/chapter/Quality-statements</a></p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">6. <b>Royal College of Radiologists (2014)</b>. <i>Recommendations for Cross-Sectional Imaging in Cancer Management</i>. London: RCR.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">7. <b>Cacicedo J</b>, <b>Navarro A</b>, <b>Del Hoyo O, et al. </b>(2016). Role of fluorine-18 flourodeoxyglucose PET-CT in head and neck oncology: the point of view of the radiation oncologist. <i>British Journal of Radiology</i>, <b>89</b>: 20160217.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">8. <b>Grégoire V</b>, <b>Thorwarth D</b>, <b>Lee JA. </b>(2018). Molecular imaging-guided radiotherapy for the treatment of head-and-neck squamous cell carcinoma: does it fulfill the promises? <i>Seminars in Radiation Oncology</i>, <b>28</b>(1): 35–45.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">9. <b>Mehanna H</b>, <b>Wong WL</b>, <b>McConkey CC, et al. </b>(2016). PET-CT surveillance versus neck dissection in advanced head and neck cancer. <i>New England Journal of Medicine</i>, <b>374</b>: 1444–1454.</p><p class="s74" style="padding-top: 4pt;padding-left: 20pt;text-indent: -13pt;text-align: justify;">10. <b>Beswick DM</b>, <b>Gooding WE</b>, <b>Johnson JT</b>, <b>Branstetter BF </b>4th (2012). Temporal patterns of head and neck squamous cell carcinoma recurrence with positron-emission tomography/ computed tomography monitoring. <i>Laryngoscope</i>, <b>122</b>(7): 1512–1517.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: left;">11. <b>Bray F</b>, <b>Ferlay J</b>, <b>Soerjomataram I</b>, <b>Siegel RL</b>, <b>Torre LA</b>, <b>Jemal A. </b>(2018). <b>Global Cancer Statistics </b>2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 26 Cancers in 185 Countries. CA: A <i>Cancer Journal for Clinicians</i>, <b>68</b>: 394–424.</p><p class="s75" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: left;"><span class="s74">12. </span>Perros P<span class="s74">, </span>Boelaert K<span class="s74">, </span>Colley S, et al. <span class="s74">(2014). </span>British Thyroid Association guideline for the management of thyroid cancer. <i>Clinical Endocrinology</i>, 81<a href="https://onlinelibrary.wiley.com/doi/pdf/10.1111/cen.12515" class="a" target="_blank">(Supp1): 1–122 https:// </a><span class="s74">onlinelibrary.wiley.com/doi/pdf/10.1111/cen.12515.</span></p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: justify;">13. <b>Tuttle RM</b>, <b>Haugen B</b>, <b>Perrier ND. </b>(2017).The updated AJCC/tnm staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why? <i>Thyroid</i>, <b>27</b>(6): 751–756.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: left;">14. <b>Hoang JK</b>, <b>Branstetter BF </b>4th, <b>Gafton AR</b>, <b>Lee WK</b>, <b>Glastonbury CM. </b>(2013). Imaging of thyroid carcinoma with CT and MRI: approaches to common scenarios. <i>Cancer Imaging</i>, <b>13</b>(1):128–139.</p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part21.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part23.htm">Далее &gt;</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
